title: Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.
abstract: Twenty-two patients with acute myeloid leukemia (AML), having a median age of 48.3 years (range 26-70; 10 male, 12 female), were treated with 4'-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) 100 mg/m2 and cytosine arabinoside (AraC) 2 x 1000 mg/m2i.v. on days 1-5. There were 2M1,8 M2, 9 M4, 2M4 Eo, and 1 M5a. Of these, 12 achieved a complete remission, 3 a partial remission and 6 did not respond. The median remission duration was 9.0 months and the median overall survival 8.1 months. Side-effects of induction consisted mainly of haematological toxicity and infections with a median duration of WHO-grade-4 granulopenia and thrombopenia of 20 and 28 days respectively. Organ toxicity was mild with mucositis and cutaneous and liver toxicity being experienced by only a few patients. There was one treatment-related death. Five-day m-AMSA and intermediate-dose AraC is an easy-to-handle condensed treatment schedule with tolerable toxicity. Its effectiveness in relapsed and refractory AML is comparable to combinations of high-dose AraC with m-AMSA, anthracyclines or etoposide.
authors.affiliation: Department of Haematology and Oncology, Hannover Medical School, Federal Republic of Germany.
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: S
authors.initials: S
authors.lastname: Giller
authors.forename: F
authors.initials: F
authors.lastname: Hinrichs
authors.forename: A
authors.initials: A
authors.lastname: Baars
authors.forename: J
authors.initials: J
authors.lastname: Meran
authors.forename: A
authors.initials: A
authors.lastname: Körfer
authors.forename: H
authors.initials: H
authors.lastname: Link
authors.forename: H
authors.initials: H
authors.lastname: Poliwoda
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000677:Amsacrine; D003561:Cytarabine